Literature DB >> 7810516

Screening and management of microalbuminuria in patients with diabetes mellitus: recommendations to the Scientific Advisory Board of the National Kidney Foundation from an ad hoc committee of the Council on Diabetes Mellitus of the National Kidney Foundation.

P H Bennett1, S Haffner, B L Kasiske, W F Keane, C E Mogensen, H H Parving, M W Steffes, G E Striker.   

Abstract

All individuals with diabetes mellitus should be screened yearly with a spot urine albumin:creatinine ratio to identify those who are at increased risk for the development of complications of diabetes mellitus, including nephropathy, retinopathy, and cardiovascular disease. Once these high-risk individuals are appropriately identified, it is recommended that therapy with an angiotensin-converting enzyme (ACE) inhibitor be initiated. In addition, cardiovascular risk factors should be investigated, and when appropriate, therapeutic interventions should be initiated according to existing recommendations.

Entities:  

Mesh:

Year:  1995        PMID: 7810516     DOI: 10.1016/0272-6386(95)90636-3

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  40 in total

Review 1.  Microalbuminuria in diabetes mellitus.

Authors:  Sheldon W Tobe; Philip Alan McFarlane; David Malcolm Naimark
Journal:  CMAJ       Date:  2002-09-03       Impact factor: 8.262

Review 2.  Screening, prevention, counseling, and treatment for the complications of type II diabetes mellitus. Putting evidence into practice.

Authors:  S Vijan; D L Stevens; W H Herman; M M Funnell; C J Standiford
Journal:  J Gen Intern Med       Date:  1997-09       Impact factor: 5.128

3.  Development of an enhanced chemiluminescence immunoassay (CLIA) for detecting urinary albumin.

Authors:  Elham Sadat Aghaei Meibodi; Maedeh Darziani Azizi; Malieh Paknejad; Bagher Larijani; Kobra Omidfar
Journal:  Mol Biol Rep       Date:  2012-10-07       Impact factor: 2.316

4.  Indications for and utilization of ACE inhibitors in older individuals with diabetes. Findings from the National Health and Nutrition Examination Survey 1999 to 2002.

Authors:  Allison B Rosen
Journal:  J Gen Intern Med       Date:  2006-04       Impact factor: 5.128

Review 5.  Lisinopril. A review of its pharmacology and use in the management of the complications of diabetes mellitus.

Authors:  K L Goa; M Haria; M I Wilde
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

Review 6.  The relationship between glucose control and the development and progression of diabetic nephropathy.

Authors:  Carrie A Phillips; Mark E Molitch
Journal:  Curr Diab Rep       Date:  2002-12       Impact factor: 4.810

Review 7.  Appropriate drug therapy for improving outcomes in diabetic nephropathy.

Authors:  Robert D Toto
Journal:  Curr Diab Rep       Date:  2002-12       Impact factor: 4.810

8.  Is oxidative stress related to childhood urolithiasis?

Authors:  Nilufer Göknar; Faruk Oktem; Engin Arı; Aysegul Doğan Demir; Emel Torun
Journal:  Pediatr Nephrol       Date:  2014-02-14       Impact factor: 3.714

9.  Effects of aggressive approach to the multiple risk factors for diabetic nephro-pathy on proteinuria reduction in diabetes type 2 patients.

Authors:  Belma Ascić-Buturović; Mirsad Kacila; Mehmed Kulić
Journal:  Bosn J Basic Med Sci       Date:  2009-02       Impact factor: 3.363

10.  Association of D-dimer with microalbuminuria in patients with type 2 diabetes mellitus.

Authors:  Ichiro Wakabayashi; Hiroshi Masuda
Journal:  J Thromb Thrombolysis       Date:  2007-10-11       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.